Tesamorelin (Egrifta): An Evidence-Graded Profile

Tesamorelin, sold as Egrifta, is one of the few peptides in this space that actually has strong, FDA-grade human evidence behind it. The catch: almost all of that evidence comes from one specific group of patients. And a lot of the way the compound gets marketed elsewhere goes well past what those studies ever showed.

What it is

Tesamorelin is a lab-made copy of a natural body signal called growth hormone-releasing hormone, or GHRH. It is not growth hormone itself. Instead, it nudges the pituitary gland (a small gland at the base of the brain) to release your own growth hormone in the natural, on-and-off rhythm the body normally uses. That, in turn, raises a related hormone called insulin-like growth factor-1, or IGF-1. You take it as a once-a-day subcutaneous (under the skin) injection. The FDA first approved it in 2010 to reduce excess visceral fat (the deep fat packed around the organs in the belly) in adults with HIV-associated lipodystrophy, a condition that changes how the body stores fat.

The claims

For its approved use, the claim is narrow and well backed up: it shrinks excess belly fat in people with HIV who have lipodystrophy. Step outside that lane, though, and tesamorelin gets pushed for all sorts of things — general fat loss, “anti-aging,” bodybuilding cutting phases, better sleep, and lowering liver fat in ordinary people. These bigger claims are exactly where the marketing pulls away from the actual evidence.

What the evidence actually shows

The approval was built on two large, carefully run phase 3 trials called LIPO-010 and CTR-1011 (together, roughly 800 HIV patients). These were randomized and placebo-controlled, meaning people were sorted by chance into a tesamorelin group or a dummy-injection group, which is the gold standard for telling whether a drug really works. Compared with the placebo, tesamorelin cut visceral fat by about 15-18%, measured by CT scan (a detailed imaging scan) over 26 weeks. When researchers pooled the results, they also saw modest gains in lean (muscle) mass and drops in trunk fat and triglycerides (a type of fat in the blood). One important detail: the benefit fades once you stop the drug, so it is not a one-and-done fix. The label says plainly that this is not a weight-loss drug — it had no effect on overall body weight.

A separate, smaller trial (Stanley et al., Lancet HIV, 2019; 61 participants over 12 months) found that tesamorelin lowered liver fat and slowed the worsening of fibrosis (scarring of the liver) in people who had both HIV and fatty liver disease. That is an encouraging early signal, but the study was small — and, once again, it looked only at people with HIV.

Here is what is missing: there are no comparable randomized trials showing real, lasting benefit in healthy adults, athletes, or anyone without HIV who just wants to lose fat for looks. The strong grade below applies to the group that was actually studied — not to the general public.

Legal and regulatory status

In the United States, tesamorelin is a prescription drug. The original Egrifta was followed by updated versions: Egrifta SV (the F4 formulation) and, most recently, Egrifta WR (the F8 formulation), which the FDA approved on March 25, 2025. Egrifta WR is still a daily injection, but because it is more concentrated, it only needs to be reconstituted (mixed from powder into liquid before use) once a week instead of every day. Every one of these approvals is still limited to HIV-associated lipodystrophy — there is no approval for general weight or fat loss. And for athletes, the World Anti-Doping Agency bans tesamorelin at all times as a growth hormone-releasing factor under category S2.

Safety

This is a real drug with real risks, all spelled out in its FDA labeling. The most consistent concerns are raised IGF-1 levels (which carry a theoretical cancer worry), trouble handling blood sugar and worsening glucose control, and fluid retention that can show up as swelling, joint pain, and carpal tunnel syndrome (numbness and tingling from a pinched nerve in the wrist). Reactions at the injection site are common. It should not be used during pregnancy, by people with active cancer, or by those with a disruption of the hypothalamic-pituitary axis (the brain-to-gland signaling system that controls these hormones). Its long-term effects on the heart are not established. And compounded or research-grade “gray market” tesamorelin adds even more unknowns around purity and dosing. None of this is medical advice.

Bottom line

For its approved use — visceral fat in HIV-associated lipodystrophy — tesamorelin has solid randomized evidence and is one of the better-studied peptides out there. For everything else it gets sold for, the human data simply isn’t there, and the safety profile is not something to shrug off. Judge it by the group it was actually tested in.

Evidence grade: 8/10 · Good (for HIV-associated lipodystrophy only; no comparable evidence in the general population).

Sources

• FDA approves tesamorelin for HIV-related lipodystrophy (AJHP)
• Clinical Review Report: Tesamorelin (Egrifta) — Results, covering the LIPO-010 and CTR-1011 phase 3 RCTs (NCBI Bookshelf)
• Tesamorelin reduces liver fat and fibrosis progression in people with HIV and NAFLD — report of Stanley et al., Lancet HIV 2019 (aidsmap)
• EGRIFTA SV (tesamorelin) prescribing information / label (DailyMed)
• Theratechnologies Receives FDA Approval for EGRIFTA WR (Tesamorelin F8) — March 25, 2025 (GlobeNewswire)
• WADA Prohibited List (S2. Peptide Hormones, Growth Factors, Related Substances and Mimetics)